Tags

Type your tag names separated by a space and hit enter

Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine.
Bull World Health Organ. 2000; 78(5):693-8.BW

Abstract

Although the introduction of tissue culture vaccines for rabies has dramatically improved the immunogenicity and safety of rabies vaccines, they are often prohibitively expensive for developing countries. To examine whether smaller doses of these vaccines could be used, we tested the safety and immunogenicity of purified chick embryo cell vaccine (PCECV) on 211 patients in Thailand with World Health Organization (WHO) category II and III exposures to rabies. The patients presented at two Thai hospitals and were randomized into three groups. Patients in Group 1 received 0.1 ml PCECV intradermally at two sites on days 0, 3, 7, and at one site on days 30 and 90. Group 2 was treated similarly, except that purified Vero cell rabies vaccine (PVRV) was used instead of PCECV. Group 3 received 1.0 ml PCECV intramuscularly on days 0, 3, 7, 14, 30 and 90. After 0, 3, 7, 14, 30 and 90 days serum was collected from the subjects and the geometric mean titres (GMTs) of rabies virus neutralizing antibody determined. After 14 days the GMT of 59 patients vaccinated intradermally with PCECV was equivalent to that of patients who received PVRV. Adverse reactions were more frequent in patients who received vaccines intradermally, indicating the reactions were associated with the route of injection, rather than the vaccine per se. We conclude that PCECV is a safe and highly immunogenic vaccine for postexposure rabies vaccination when administered intradermally in 0.1-ml doses using the two-site method ("2,2,2,0,1,1") recommended by WHO.

Authors+Show Affiliations

College of Veterinary Medicine, Kansas State University, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

10859864

Citation

Briggs, D J., et al. "Antibody Response of Patients After Postexposure Rabies Vaccination With Small Intradermal Doses of Purified Chick Embryo Cell Vaccine or Purified Vero Cell Rabies Vaccine." Bulletin of the World Health Organization, vol. 78, no. 5, 2000, pp. 693-8.
Briggs DJ, Banzhoff A, Nicolay U, et al. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ. 2000;78(5):693-8.
Briggs, D. J., Banzhoff, A., Nicolay, U., Sirikwin, S., Dumavibhat, B., Tongswas, S., & Wasi, C. (2000). Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bulletin of the World Health Organization, 78(5), 693-8.
Briggs DJ, et al. Antibody Response of Patients After Postexposure Rabies Vaccination With Small Intradermal Doses of Purified Chick Embryo Cell Vaccine or Purified Vero Cell Rabies Vaccine. Bull World Health Organ. 2000;78(5):693-8. PubMed PMID: 10859864.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. AU - Briggs,D J, AU - Banzhoff,A, AU - Nicolay,U, AU - Sirikwin,S, AU - Dumavibhat,B, AU - Tongswas,S, AU - Wasi,C, PY - 2000/6/22/pubmed PY - 2000/7/25/medline PY - 2000/6/22/entrez SP - 693 EP - 8 JF - Bulletin of the World Health Organization JO - Bull World Health Organ VL - 78 IS - 5 N2 - Although the introduction of tissue culture vaccines for rabies has dramatically improved the immunogenicity and safety of rabies vaccines, they are often prohibitively expensive for developing countries. To examine whether smaller doses of these vaccines could be used, we tested the safety and immunogenicity of purified chick embryo cell vaccine (PCECV) on 211 patients in Thailand with World Health Organization (WHO) category II and III exposures to rabies. The patients presented at two Thai hospitals and were randomized into three groups. Patients in Group 1 received 0.1 ml PCECV intradermally at two sites on days 0, 3, 7, and at one site on days 30 and 90. Group 2 was treated similarly, except that purified Vero cell rabies vaccine (PVRV) was used instead of PCECV. Group 3 received 1.0 ml PCECV intramuscularly on days 0, 3, 7, 14, 30 and 90. After 0, 3, 7, 14, 30 and 90 days serum was collected from the subjects and the geometric mean titres (GMTs) of rabies virus neutralizing antibody determined. After 14 days the GMT of 59 patients vaccinated intradermally with PCECV was equivalent to that of patients who received PVRV. Adverse reactions were more frequent in patients who received vaccines intradermally, indicating the reactions were associated with the route of injection, rather than the vaccine per se. We conclude that PCECV is a safe and highly immunogenic vaccine for postexposure rabies vaccination when administered intradermally in 0.1-ml doses using the two-site method ("2,2,2,0,1,1") recommended by WHO. SN - 0042-9686 UR - https://www.unboundmedicine.com/medline/citation/10859864/Antibody_response_of_patients_after_postexposure_rabies_vaccination_with_small_intradermal_doses_of_purified_chick_embryo_cell_vaccine_or_purified_Vero_cell_rabies_vaccine_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/10859864/ DB - PRIME DP - Unbound Medicine ER -